Form 4: Bristol-Myers Squibb CFO David Elkins Reports Changes in Beneficial Ownership

David Elkins, EVP and CFO of Bristol-Myers Squibb, reports transactions involving common stock and derivative securities, including vesting of market share units and performance shares.

Summary

• David Elkins, the EVP and CFO of Bristol-Myers Squibb, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• The transactions occurred on March 10, 2024, and involve common stock and derivative securities, specifically market share units and performance shares.
• Elkins acquired shares through the vesting of market share units and the distribution of performance shares earned under a long-term performance award.
• He also disposed of shares to cover tax obligations related to the vesting of awards.
• Some market share units were cancelled because the minimum payout factor was not achieved.
• Following these transactions, Elkins directly owns 194,968 shares of common stock and indirectly owns 215.72 shares through the BMS Savings and Investment Program.
• He also holds various market share units and performance shares that will vest in the future.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting transactions. The vesting of awards is generally positive, but the cancellation of some units is slightly negative.

Positives

• The vesting of market share units and distribution of performance shares indicate that certain performance targets were met, at least partially.
• Elkins' continued holding of a significant number of shares demonstrates his alignment with the company's success.

Negatives

• The cancellation of market share units due to the minimum payout factor not being achieved suggests that some performance goals were not fully met.
• The disposal of shares to cover tax obligations reduces Elkins' direct ownership, although this is a common practice.

Risks

• Fluctuations in Bristol-Myers Squibb's stock price could impact the value of Elkins' holdings and future payouts from market share units and performance shares.
• Changes in the company's performance or compensation policies could affect the value and vesting of future awards.

Future Outlook

The document indicates future vesting dates for market share units and performance shares, suggesting continued equity-based compensation for the reporting person.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the alignment of management's interests with those of shareholders. The vesting of market share units and performance shares is a common practice in the pharmaceutical industry to incentivize performance and retain key executives.

Comparison to Industry Standards

• Equity-based compensation, including market share units and performance shares, is a standard practice among large pharmaceutical companies like Johnson & Johnson (JNJ), Pfizer (PFE), and Merck (MRK).
• The specific terms of these awards, such as vesting schedules and performance metrics, vary from company to company.
• The payout factors for the market share units (60%-200% and 80%-225%) are within the typical range for such awards in the industry.
• The use of Total Shareholder Return (TSR) as a performance metric for performance shares is also a common practice.

Stakeholder Impact

• The transactions have a minimal direct impact on shareholders, employees, customers, suppliers, and creditors.
• The vesting of equity-based compensation aligns management's interests with those of shareholders.

Next Steps

• Continued monitoring of Elkins' beneficial ownership filings for future transactions.
• Tracking the vesting of remaining market share units and performance shares.

Key Dates